May 2005
Volume 46, Issue 13
Free
ARVO Annual Meeting Abstract  |   May 2005
IOP–Lowering Efficacy of Bimatoprost 0.03% and Travoprost 0.004% in Patients With Glaucoma or Ocular Hypertension
Author Affiliations & Notes
  • L.B. Cantor
    Department of Ophthalmology, Indiana Univ School of Medicine, Indianapolis, IN
  • J. Hoop
    Department of Ophthalmology, Indiana Univ School of Medicine, Indianapolis, IN
  • L. Morgan
    Department of Ophthalmology, Indiana Univ School of Medicine, Indianapolis, IN
  • Bimatoprost–Travoprost Study Group
    Department of Ophthalmology, Indiana Univ School of Medicine, Indianapolis, IN
  • Footnotes
    Commercial Relationships  L.B. Cantor, Allergan C; J. Hoop, None; L. Morgan, None.
  • Footnotes
    Support  None.
Investigative Ophthalmology & Visual Science May 2005, Vol.46, 2451. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      L.B. Cantor, J. Hoop, L. Morgan, Bimatoprost–Travoprost Study Group; IOP–Lowering Efficacy of Bimatoprost 0.03% and Travoprost 0.004% in Patients With Glaucoma or Ocular Hypertension . Invest. Ophthalmol. Vis. Sci. 2005;46(13):2451.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Abstract: : Purpose: To evaluate the IOP–lowering efficacy of bimatoprost and travoprost for the treatment of glaucoma and ocular hypertension. Methods: Randomized, investigator–masked, parallel–group clinical trial. After completing a washout from all glaucoma medications, patients (n=158) were randomized to bimatoprost or travoprost for 6 months. Visits were at baseline, week 1, and months 1, 3, and 6. IOP was measured at 9 AM at each visit and also at 1 and 4 PM at baseline and months 3 and 6. This is an interim analysis of an ongoing clinical trial. Results: At the baseline visit, there were no significant between–group differences in IOP at 9AM, 1PM, or 4PM (P>.731). After 6 months of therapy, both medications provided significant mean reductions from baseline IOP at every time point (P<.001). Bimatoprost provided greater mean IOP reductions from baseline than travoprost at every time point at each follow up study visit and these differences were statistically significant at every visit at 9AM. After 6 months of therapy, the mean IOP reduction at 9AM was 7.2 mm Hg (28.3%) with bimatoprost (n=63) and 5.4 mm Hg (22.3%) with travoprost (n=60) (P=.005). At 1PM, the mean IOP reduction was 6.0 mm Hg with bimatoprost (25.7%) and 4.9 mm Hg (21.1%) with travoprost (P=.058). Finally, bimatoprost continued to provide greater IOP lowering than travoprost at 4 PM, with a mean bimatoprost–provided IOP reduction of 5.5 mm Hg (23.3%) versus a mean travoprost–provided IOP reduction of 4.3 mm Hg (18.1%, P=.086). Both study medications were well tolerated and ocular redness was the most commonly reported adverse event in both treatment groups. Conclusions: Bimatoprost provided greater mean IOP reductions than travoprost.

Keywords: clinical (human) or epidemiologic studies: treatment/prevention assessment/controlled 
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×